Biossil
The Toronto-based firm uses AI to identify and develop drug candidates from previously failed pharmaceutical projects.
Canadian company (ON)Why Boreal Signal tracks this company
We track Biossil to understand how its decisions in ai-driven biotech discovery platform affect the market and its Canadian operations.
- Coverage focus
- AI-driven biotech discovery platform
- Related stories
- 3
- Last reviewed
- Sep 29, 2026
Profiles are based on Boreal Signal reporting and are updated as new stories are published.
Biossil Repurposes Failed Drug Candidates Using Advanced AI Platform
The challenge of drug discovery has historically been defined by attrition. A molecule can show immense promise, only to fall through the rigorous gauntlet of preclinical and early clinical testing for reasons...
Biossil Rethinks Drug Development: Mapping Therapeutics Through Semantic Vectors
The core strength of Biossil Inc. lies not in molecular engineering, but in its sophisticated application of natural language processing (NLP) to solve a systemic problem: the massive loss of therapeutic value...
Biossil raises $153M; CEO confirms building integrated AI biotech infrastructure
This financing signals that translating advanced AI insights into clinical practice requires building complex, dedicated physical infrastructure across both US and Canadian sites.